SK Bioscience Co Ltd (302440) - Cash Flow Conversion Efficiency
Based on the latest financial reports, SK Bioscience Co Ltd (302440) has a cash flow conversion efficiency ratio of 0.010x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩20.65 Billion ≈ $14.00 Million USD) by net assets (₩2.07 Trillion ≈ $1.41 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
SK Bioscience Co Ltd - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how SK Bioscience Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does SK Bioscience Co Ltd carry for a breakdown of total debt and financial obligations.
SK Bioscience Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of SK Bioscience Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ecopro Co. Ltd
KQ:086520
|
0.109x |
|
Azelis Group NV
BR:AZE
|
0.083x |
|
Hanesbrands Inc
NYSE:HBI
|
0.062x |
|
Société BIC SA
PA:BB
|
0.025x |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
|
0.021x |
|
Guangdong Advertising Co Ltd
SHE:002400
|
0.025x |
|
Beijing TRS Information Tech
SHE:300229
|
-0.003x |
|
ISC Co. Ltd
KQ:095340
|
0.030x |
Annual Cash Flow Conversion Efficiency for SK Bioscience Co Ltd (2018–2024)
The table below shows the annual cash flow conversion efficiency of SK Bioscience Co Ltd from 2018 to 2024. For the full company profile with market capitalisation and key ratios, see how much is SK Bioscience Co Ltd worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩2.02 Trillion ≈ $1.37 Billion |
₩-128.02 Billion ≈ $-86.76 Million |
-0.063x | -467.52% |
| 2023-12-31 | ₩1.70 Trillion ≈ $1.15 Billion |
₩29.35 Billion ≈ $19.89 Million |
0.017x | +124.01% |
| 2022-12-31 | ₩1.74 Trillion ≈ $1.18 Billion |
₩-124.96 Billion ≈ $-84.68 Million |
-0.072x | -121.41% |
| 2021-12-31 | ₩1.60 Trillion ≈ $1.09 Billion |
₩536.59 Billion ≈ $363.64 Million |
0.335x | -26.47% |
| 2020-12-31 | ₩263.79 Billion ≈ $178.77 Million |
₩120.22 Billion ≈ $81.47 Million |
0.456x | +386.10% |
| 2019-12-31 | ₩232.73 Billion ≈ $157.72 Million |
₩21.82 Billion ≈ $14.79 Million |
0.094x | +32.58% |
| 2018-12-31 | ₩210.73 Billion ≈ $142.81 Million |
₩14.90 Billion ≈ $10.10 Million |
0.071x | -- |
About SK Bioscience Co Ltd
SK bioscience Co.,Ltd. engages in the research and development, production, and distribution of vaccines and biopharmaceuticals in Korea and internationally. Its product portfolio includes Skycellflu, a cell cultured influenza surface antigen vaccine; Skycellflu 4-ga pre-filled syringe; pneumococcal vaccine for adult and infant; Skyzoster, a shingles virus vaccine; and Sky Baricella for the preve… Read more